Swiss biopharma Idorsia gave out few details Tuesday about a potential $440.8 million (400 million CHF) deal with an unnamed company that would include licensing rights to some of Idorsia’s products …
Read Full Story at source (may require registration)
- What is Meant by “Discovery” in Sales? A Strategy for Building Trust and Driving Conversions - March 12, 2025
- How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024